As of November 6, 2026, Entrada Therapeutics, Inc. is a publicly traded company (Nasdaq: TRDA). The largest holder reporting an active stake on Schedule 13D is 5AM Ventures V, L.P., at 10.8%. No bankruptcy or receivership appears in its SEC Form 8-K filings (Schedule 13D/A, November 18, 2025).
Is this your company?
About to sign with, pay or invest in Entrada Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Entrada Therapeutics, Inc. a real, registered company?
- Entrada Therapeutics, Inc. files with the SEC under CIK 1689375 (its SEC filings).
- Its shares are listed under the ticker TRDA on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ENTRADA THERAPEUTICS, INC. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names MPM BioVentures 2014, L.P. (filed 2026-09-10).
Who are Entrada Therapeutics, Inc.'s owners and officers?
Entrada Therapeutics, Inc.: incorporated in Delaware; business address in Boston, Massachusetts; industry Pharmaceutical Preparations (Schedule 13D/A, 2026-09-10).
| Report | Holder | Share |
|---|---|---|
| Schedule 13D/A, 2026-09-10 | Mpm Bioventures 2014, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-14 | Tcg Crossover Gp I, LLC | 2.7% |
| Schedule 13G, 2025-11-25 | Tcg Crossover Gp I, LLC | 5% |
| Schedule 13D/A, 2025-11-18 | 5am Ventures V, L.P. | 10.8% |
| Schedule 13G/A, 2025-11-14 | T. Rowe Price Associates, Inc. | 0.9% |
| Schedule 13G/A, 2025-08-14 | Janus Henderson Group PLC | 4% |
| Schedule 13G/A, 2025-08-14 | T. Rowe Price Associates, Inc. | 6.8% |
Questions about who owns Entrada Therapeutics, Inc.
Who owns Entrada Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Entrada Therapeutics, Inc.: 5am Ventures V, L.P. (10.8%, Schedule 13D/A, filed 2025-11-18) and Mpm Bioventures 2014, L.P. (9.9%, Schedule 13D/A, filed 2026-09-10).
Who are the largest shareholders of Entrada Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Entrada Therapeutics, Inc. on this page are 5am Ventures V, L.P. (10.8%) and Mpm Bioventures 2014, L.P. (9.9%).
When did 5am Ventures V, L.P. buy into Entrada Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from 5am Ventures V, L.P. on this page is the Schedule 13D/A, filed 2025-11-18, reporting 10.8%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Entrada Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Entrada Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Entrada Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Entrada Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Baker Bros. Advisors LP, a 10% owner: 4,691,392 shares (12.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-11-24).
- Baker Bros. Advisors (GP) LLC, a 10% owner: 4,691,392 shares (12.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-11-24).
- , a 10% owner: 4,691,392 shares (12.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-11-24).
- , a 10% owner: 4,691,392 shares (12.0% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-11-24).
- MPM Asset Management Investors BV2018 LLC, a 10% owner: 3,885,115 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-09-09).
Shares outstanding: 39,150,334 as of 2026-10-31, from the company's latest SEC cover page.
How much has Entrada Therapeutics, Inc. raised?
No fundraising or offering filing from Entrada Therapeutics, Inc. is on file with us.
Keep reading
More on Entrada Therapeutics, Inc. and the records around it.
Entrada Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Sep 2026
Companies that share a holder
- 5AM Ventures V, L.P. also filed stake reports on 1 other company: Rallybio Corp (May 2026)
- MPM BioVentures 2014, L.P. also filed stake reports on 1 other company: WEREWOLF THERAPEUTICS, INC. (May 2026)
- TCG Crossover GP I, LLC also filed stake reports on 6 other companies: Abivax SA (Aug 2026), Vistagen Therapeutics, Inc. (Aug 2026), Savara Inc. (Feb 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/entrada-therapeutics